Among women aged 20 to 24 years who were screened for cervical cancer, rates decreased by 79, 80 percent for CIN2+, CIN3+.

the vaccine was 100% effective in preventing cervical intraepithelial neoplasia (CIN)1-3 and adenocarcinoma in situ (AIS) associated with HPV 16 and 18. In the FUTURE I intention-to-treat group ...